Boehringer Ingelheim has expanded its oncology pipeline with the acquisition of a preclinical small molecule program from Accent Therapeutics. The asset, which targets tumors characterized by high interferon-stimulated gene (ISG) expression, is positioned as a potentially first-in-class therapy. Boehringer will assume full global responsibility for the program’s research, development, manufacturing, and commercialization. The deal aligns with Boehringer’s strategy to develop cancer cell–di...